Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06459973 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by MediLink Therapeutics (Suzhou) Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 252
- Enrollment target
- 20
- Study locations
NCT06459973: Recruiting Phase 1 study of Advanced Solid Tumors, sponsored by MediLink Therapeutics (Suzhou) Co..
NCT06459973 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by MediLink Therapeutics (Suzhou) Co.. The registered enrollment target is 252 participants, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (28% higher). The trial reports 20 study locations across 19 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06459973, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by MediLink Therapeutics (Suzhou) Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 252 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a multicenter, open-label, phase I/II study of YL205 in China to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of YL205 in the following selected patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG intravenous (IV) infusion
Study Locations (20)
Henan
- Anyang Cancer Hospital - Anyang
- Henan Cancer Hospital - Zhengzhou
Colorado
- Sarah Cannon Research Institute (SCRI)- Denver - Denver
Connecticut
- Yale Cancer Center - New Haven
Florida
- Florida Cancer Specialists - Lake Mary - Lake Mary
Kentucky
- Norton Cancer Institute - Louisville
Missouri
- Washington University School of Medicine - Center for advanced Medicine - St Louis
Nevada
- Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley - Las Vegas
New Mexico
- Southwest Women's Oncology - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2024-06-04 |
| Est. Completion | 2030-07-31 |
| Phase | Phase 1 |
What NCT06459973 shows while recruiting
NCT06459973 is an interventional study that assigns participants to a tested intervention. The registered 252 participants enrollment target is mid-sized for trials with a published cap, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (28% higher).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which intravenous (IV) infusion is the first listed.
NCT06459973 names 20 study sites across 19 states, led by Henan, Colorado, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06459973 about?
NCT06459973 is a clinical study titled "A Clinical Study of YL205 in Patients With Advanced Solid Tumors". This study is a multicenter, open-label, phase I/II study of YL205 in China to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of YL205 in the following selected patients with advanced solid tumors.
What is the current status of trial NCT06459973?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 252 participants. The study started on 2024-06-04. Estimated completion is 2030-07-31.
What conditions does trial NCT06459973 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT06459973?
The interventions under investigation include: intravenous (IV) infusion (DRUG).
Who is sponsoring clinical trial NCT06459973?
This trial is sponsored by MediLink Therapeutics (Suzhou) Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06459973 being conducted?
This trial has 20 study locations across Colorado, Connecticut, Florida, Kentucky, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06459973's enrollment target sits among peer trials
252 34th of 144 higher than 111 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02314988 · 252 participants · Phase 2
Tranexamic Acid to Reduce Blood Loss in Spine Surgery
- NCT03941756 · 252 participants · NA
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
- NCT05219617 · 252 participants · Phase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
- NCT05384158 · 252 participants · NA
Valuation in Depressed Mood, Anhedonia, and Anxiety
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI